V
Vincent Ribrag
Researcher at Institut Gustave Roussy
Publications - 371
Citations - 12607
Vincent Ribrag is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 51, co-authored 320 publications receiving 10293 citations. Previous affiliations of Vincent Ribrag include Université Paris-Saclay.
Papers
More filters
Journal ArticleDOI
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Jean-Marie Michot,Camille Bigenwald,Stéphane Champiat,Michael Collins,Franck Carbonnel,Sophie Postel-Vinay,Amandine Berdelou,Andreea Varga,Ratislav Bahleda,Antoine Hollebecque,Christophe Massard,Alina Fuerea,Vincent Ribrag,A. Gazzah,J.P. Armand,N Amellal,Eric Angevin,Nicolas Noel,Celine Boutros,Christine Mateus,Caroline Robert,Jean-Charles Soria,Aurélien Marabelle,Olivier Lambotte +23 more
TL;DR: This review focuses on the mechanisms of IRAE generation, putative relationship between dysimmune toxicity and antitumour efficacy, as a basis for management guidelines.
Journal ArticleDOI
Treatment of Older Patients with Mantle-Cell Lymphoma
Hanneke C. Kluin-Nelemans,Eva Hoster,Olivier Hermine,Jan Walewski,Marek Trneny,Christian H. Geisler,Stephan Stilgenbauer,Catherine Thieblemont,Ursula Vehling-Kaiser,J.K. Doorduijn,Bertrand Coiffier,Roswitha Forstpointner,H. Tilly,Lothar Kanz,P. Feugier,Michal Szymczyk,Michael Hallek,Stephan Kremers,Gérard Lepeu,Laurence Sanhes,Josée M. Zijlstra,R. Bouabdallah,P. J. Lugtenburg,Margaret Macro,Michael Pfreundschuh,Vít Procházka,F. Di Raimondo,Vincent Ribrag,Michael Uppenkamp,M. Andre,Wolfram Klapper,Wolfgang Hiddemann,Michael Unterhalt,Martin Dreyling +33 more
TL;DR: R-CHOP induction followed by maintenance therapy with rituximab is effective for older patients with mantle-cell lymphoma.
Journal ArticleDOI
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
Olivier Hermine,Olivier Hermine,Eva Hoster,Jan Walewski,André Bosly,Stephan Stilgenbauer,Catherine Thieblemont,Michal Szymczyk,Reda Bouabdallah,Michael Kneba,Michael Hallek,Gilles Salles,Pierre Feugier,Vincent Ribrag,Josef Birkmann,Roswitha Forstpointner,Corinne Haioun,Mathias Hänel,Rene-Olivier Casasnovas,Jürgen Finke,Norma Peter,Kamal Bouabdallah,Catherine Sebban,Thomas Fischer,Ulrich Dührsen,Bernd Metzner,Georg Maschmeyer,Lothar Kanz,Christian Schmidt,Richard Delarue,Nicole Brousse,Wolfram Klapper,Elizabeth Macintyre,Marie-Hélène Delfau-Larue,Christiane Pott,Wolfgang Hiddemann,Michael Unterhalt,Martin Dreyling +37 more
TL;DR: Investigating whether the introduction of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation (ASCT) improves outcome found it should be considered standard of care in patients aged 65 years or younger with mantle cell lymphoma.
Journal ArticleDOI
Results of Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue in 22 Patients With Refractory or Recurrent Primary CNS Lymphoma or Intraocular Lymphoma
Carole Soussain,Florence Suzan,Khê Hoang-Xuan,Nathalie Cassoux,Vincent Levy,Nabih Azar,Coralie Belanger,Eddine Achour,Vincent Ribrag,Sophie Gerber,Jean-Yves Delattre,Véronique Leblond +11 more
TL;DR: IC + HCR proved feasible and effective in patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma and the entire procedure seemed to be most toxic in patients > or = 60 years.
Journal ArticleDOI
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
Steven Le Gouill,Catherine Thieblemont,Lucie Oberic,Anne Moreau,Krimo Bouabdallah,Caroline Dartigeas,Gandhi Damaj,Thomas Gastinne,Vincent Ribrag,Pierre Feugier,Olivier Casasnovas,Hacene Zerazhi,Corinne Haioun,Hervé Maisonneuve,Roch Houot,Fabrice Jardin,Eric Van Den Neste,Olivier Tournilhac,Katell Le Du,Franck Morschhauser,Guillaume Cartron,Luc-Matthieu Fornecker,Danielle Canioni,Mary Callanan,Marie C. Béné,Gilles Salles,Hervé Tilly,Thierry Lamy,Remy Gressin,Olivier Hermine +29 more
TL;DR: Rituximab maintenance therapy after transplantation prolonged event‐free survival, progression‐ free survival, and overall survival among patients with mantle‐cell lymphoma who were younger than 66 years of age at diagnosis.